Decreased Plasma Maresin 1 Concentration Is Associated with Diabetic Foot Ulcer

Tian, Miao; Huang, Bangliang; He, Niexia; Sun, Lihua; Du, Guang-sheng; Gong, Xin; Xu, Yong; Zheng, Yi; Wang, Cong-Yi; Qu, Hua

doi:10.1155/2020/4539035

Cited by 21 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, 17-HDHA and PD1 were decreased in white adipose tissue of db/db mice, consistent with studies using diet-induced obese mice, although 18-HEPE levels were elevated compared to controls ( 37 ). In type 2 diabetic subjects, circulating maresin 1 (MaR1) levels were decreased compared to controls; furthermore, MaR1 was further decreased in those type 2 diabetics with foot ulcers ( 40 ). MaR1 is of significance given its role in regulating murine insulin sensitivity and adipose tissue inflammation in models of genetic and diet-induced obesity ( 46 ).…”

Section: Obesity Promotes a Signature Of Spm Deficiencymentioning

confidence: 99%

Obesity-Driven Deficiencies of Specialized Pro-resolving Mediators May Drive Adverse Outcomes During SARS-CoV-2 Infection

et al. 2020

View full text Add to dashboard Cite

Obesity is a major independent risk factor for increased morbidity and mortality upon infection with Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2), which is responsible for the current coronavirus disease pandemic (COVID-19). Therefore, there is a critical need to identify underlying metabolic factors associated with obesity that could be contributing toward increased susceptibility to SARS-CoV-2 in this vulnerable population. Here, we focus on the critical role of potent endogenous lipid metabolites known as specialized pro-resolving mediators (SPMs) that are synthesized from polyunsaturated fatty acids. SPMs are generated during the transition of inflammation to resolution and have a vital role in directing damaged tissues to homeostasis; furthermore, SPMs display anti-viral activity in the context of influenza infection without being immunosuppressive. We cover evidence from rodent and human studies to show that obesity, and its co-morbidities, induce a signature of SPM deficiency across immunometabolic tissues. We further discuss how the effects of obesity upon SARS-CoV-2 infection are likely exacerbated with environmental exposures that promote chronic pulmonary inflammation and augment SPM deficits. Finally, we highlight potential approaches to overcome the loss of SPMs using dietary and pharmacological interventions. Collectively, this mini-review underscores the need for mechanistic studies on how SPM deficiencies driven by obesity and environmental exposures may exacerbate the response to SARS-CoV-2.

show abstract

Section: Obesity Promotes a Signature Of Spm Deficiencymentioning

confidence: 99%

Obesity-Driven Deficiencies of Specialized Pro-resolving Mediators May Drive Adverse Outcomes During SARS-CoV-2 Infection

et al. 2020

View full text Add to dashboard Cite

show abstract

“…MaR1 has been identified as a new anti-inflammatory pro-resolving mediator with a vital role in metabolic disorders, including NAFLD [ 16 – 18 , 23 ]. However, limited information supports the role of MaR1 in the occurrence and development of human NAFLD.…”

Section: Discussionmentioning

confidence: 99%

Low serum Maresin-1 levels are associated with non-alcoholic fatty liver disease: a cross-sectional study

Xia

Wang

et al. 2021

Lipids Health Dis

Self Cite

View full text Add to dashboard Cite

Background Maresin-1 (MaR1) is an anti-inflammatory pro-resolving mediator and is considered a potential regulator of metabolic diseases. Non-alcoholic fatty liver disease (NAFLD) is a very common metabolic liver disease. However, little information is available on the relationship between MaR1 and NAFLD in humans. Therefore, the study explored the association between serum MaR1 levels and NAFLD. Methods A cross-sectional study was conducted in 240 Chinese people, including 116 non-NAFLD subjects and 124 NAFLD patients. Serum MaR1 levels were determined by enzyme-linked immunosorbent assay (ELISA). The association between MaR1 and NAFLD was assessed. Results Circulating MaR1 levels in NAFLD patients were markedly lower than those in non-NAFLD subjects (63.63 [59.87–73.93] vs 73.11 [65.12–84.50] pg/mL, P = 0.000). The percentages of patients with NAFLD gradually decreased with the increase of MaR1 quartiles (P < 0.001). Furthermore, serum MaR1 levels were positively associated with aspartate aminotransferase/alanine aminotransferase (AST/ALT), albumin, the albumin-globulin-ratio, and high-density lipoprotein cholesterol (HDL-C) (all P < 0.05) and negatively associated with body mass index (BMI), waist circumference, hip circumference, the waist-to-hip ratio, ALT, gamma-glutamyl transpeptidase (GGT), uric acid, triglyceride (TG), and fasting blood glucose (FBG) (all P < 0.05) after adjusting for sex and age. Binary logistic regression analysis revealed that serum MaR1 levels were significantly associated with NAFLD. Conclusions Circulating MaR1 levels were decreased in patients with NAFLD, and a negative correlation was identified between NAFLD and serum MaR1 concentrations. Decreased MaR1 might be involved in the development of NAFLD.

show abstract

“…Maresin-1 has been identi ed as a new member of pro-in ammatory regression mediators with an important role in metabolic disorders diseases, including NAFLD [14][15][16]21]. However, there is limited evidence to support the potential role of Maresin-1 in the occurrence and development of NAFLD in humans.…”

Section: Discussionmentioning

confidence: 99%

Low Serum Maresin-1 Levels Are Associated with Non-alcoholic Fatty Liver Disease: A Cross Sectional Study

Fang

Wang

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background Maresin-1 is one of anti-inflammatory pro-resolving mediators, which is considered as a potential regulator of metabolic diseases. However, little information is available on the relationship between Maresin-1 and non-alcoholic fatty liver disease (NAFLD) in humans. Therefore, this study explored the associations between serum Maresin-1 levels and NAFLD. Methods A cross-sectional study was conducted in 240 Chinese people, including 116 non-NAFLD subjects and 124 NAFLD patients. NAFLD was diagnosed by abdominal ultrasonography. Serum Maresin-1 levels were determined by ELISA. The association between Maresin-1 and NAFLD was assessed. Results Serum Maresin-1 levels in NAFLD patients were markedly lower than those in non-NAFLD subjects (63.63 [59.87–73.93] vs 73.11 [65.12–84.50] pg/mL, P = 0.000). The percentages of patients with NAFLD gradually decreased in tandem with increasing quartiles of Maresin-1 (P < 0.001). Furthermore, serum Maresin-1 levels were positively associated with AST/ALT, albumin, Albumin-globulin-ratio, and HDL-C (all P < 0.05) and negatively associated with BMI, waist circumference, hip circumference, waist-to-hip ratio, ALT, GGT, uric acid, TG, and FBG (all P < 0.05) after adjusting for sex and age. We found that serum Maresin-1 levels were significantly associated with NAFLD by binary logistic regression analysis. Conclusions Circulating Maresin-1 levels were decreased in patients with NAFLD, and there was a negative correlation between NAFLD and serum Maresin-1 concentrations. Decreased Maresin-1 might be involved in the development of NAFLD.

show abstract

Decreased Plasma Maresin 1 Concentration Is Associated with Diabetic Foot Ulcer

Cited by 21 publications

References 30 publications

Obesity-Driven Deficiencies of Specialized Pro-resolving Mediators May Drive Adverse Outcomes During SARS-CoV-2 Infection

Obesity-Driven Deficiencies of Specialized Pro-resolving Mediators May Drive Adverse Outcomes During SARS-CoV-2 Infection

Low serum Maresin-1 levels are associated with non-alcoholic fatty liver disease: a cross-sectional study

Low Serum Maresin-1 Levels Are Associated with Non-alcoholic Fatty Liver Disease: A Cross Sectional Study

Contact Info

Product

Resources

About